Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis
Launched by ISTITUTI FISIOTERAPICI OSPITALIERI · Jul 25, 2008
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
The Nail Psoriasis Severity Index (NAPSI) has been designed and successfully implemented to grade severity of psoriatic nail disease. Moreover, the utilization of the NAPSI score and a modified version of this severity index score as an instrument to monitor response to therapy has been recently documented in the medical literature .This open study involves thirty-six patients with moderate to severe nail psoriasis treated with low-dose acitretin from January 2005 to January 2007.Acitretin was given at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months. Laboratory investigations and clinical e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with moderate to severe nail psoriasis
- Exclusion Criteria:
- • premenopausal women
- • patients with hepatic, renal or metabolic diseases
- • patients with skin or symptomatic arthropathic psoriasis
- • previous systemic treatment for nail psoriasis
About Istituti Fisioterapici Ospitalieri
Istituti Fisioterapici Ospitalieri (IFO) is a leading clinical trial sponsor dedicated to advancing medical research and enhancing patient care through innovative therapeutic solutions. With a strong focus on rehabilitation and physiotherapy, IFO combines clinical expertise with state-of-the-art facilities to conduct rigorous trials across various therapeutic areas. The organization is committed to ethical research practices and collaboration with healthcare professionals, ensuring the highest standards of safety and efficacy in its clinical studies. By fostering a collaborative environment, IFO aims to contribute significantly to the development of new treatment modalities that improve the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Antonella Tosti, MD
Principal Investigator
University of Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials